Get the Stockscreener App
131.69
0.63%
0.82
Repligen Corp stock is traded at $131.69, with a volume of 612.28K.
It is up +0.63% in the last 24 hours and up +28.02% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$130.87
Open:
$131.32
24h Volume:
612.28K
Relative Volume:
0.57
Market Cap:
$7.43B
Revenue:
$763.34M
Net Income/Loss:
$51.40M
P/E Ratio:
144.97
EPS:
0.9084
Net Cash Flow:
$104.46M
1W Performance:
+1.20%
1M Performance:
+28.02%
6M Performance:
-16.70%
1Y Performance:
+4.44%
1-Day Range:
$129.70
$134.11
1-Week Range:
$126.83
$135.72
52-Week Range:
$100.99
$175.77
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
131.69 | 7.38B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
417.07 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.16 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.84 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.09 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
193.94 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-01-25 | Initiated | HSBC Securities | Buy |
| Sep-22-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
RBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its View - Insider Monkey
Billionaire Lee Ainslie’s 5 Stocks with Huge Upside Potential - Insider Monkey
Repligen Corp. Hits Day High with 8.45% Surge in Stock Price - Markets Mojo
Multi Cap Equity Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Te - GuruFocus
Repligen Corp (RGEN) Shares Surge 4.0% -- What GF Score of 79 Te - GuruFocus
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
State Street Small-Cap Equity V.I.S. Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen Corp at William Blair Growth Stock Conference Transcript - GuruFocus
RGEN Assumed by Wolfe Research -- Rating Upgraded to Outperform - GuruFocus
Wolfe Research initiates Repligen stock coverage with outperform rating By Investing.com - Investing.com Australia
Wolfe Research initiates Repligen stock coverage with outperform rating - Investing.com
Repligen Has A Cleaner Recovery Angle, But With High Valuation - Seeking Alpha
Repligen Corp stock (US7607591002): RGEN jumps after strong Nasdaq session - AD HOC NEWS
Repligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF S - GuruFocus
Repligen's $833 Million Guide: Can Analytics And China Power The Next Leg? - Smartkarma
Repligen Jumps 12% This Week as June Investor Update Approaches - Bez Kabli
Repligen (RGEN) Edges Higher Amid Bioprocessing Sector OptimismFibonacci Arc - The Legal Advocate
Hear Repligen's CEO give company overview at June 3 webcast - Stock Titan
Repligen Corp stock (US7607591002): ESG progress and growth focus draw fresh attention - AD HOC NEWS
InvestingPro’s Fair Value model predicted Repligen’s 45% decline By Investing.com - Investing.com Canada
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks - Yahoo Finance
Repligen’s 2025 Sustainability Report Highlights Carbon Emission Reductions and ESG Progress - geneonline.com
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report - Yahoo Finance
Repligen Corp (RGEN) Stock Up 4.2% and Still Undervalued -- GF S - GuruFocus
Repligen shares jump 4.1% as investors buy the dip after a sharp selloff; prior guidance update and short-covering may be factors - Quiver Quantitative
Repligen Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Why Repligen (RGEN) Stock Is Trading Up Today - Yahoo Finance
Repligen (RGEN) director granted RSUs and options in Form 4 filing - Stock Titan
Repligen (NASDAQ: RGEN) director receives new RSU and stock option awards - Stock Titan
Repligen (RGEN) director Rohin Mhatre receives RSU and option grants - Stock Titan
Repligen (RGEN) director Margaret Pax receives new RSU and stock option awards - Stock Titan
Repligen (NASDAQ: RGEN) director granted RSUs and options in equity award - Stock Titan
Repligen (RGEN) director receives new RSU and stock option grants - Stock Titan
Repligen Corp stock (US7607591002): bioprocessing specialist back in focus after latest earnings - AD HOC NEWS
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corp stock (US7607591002): RBC upgrade and Q1 2026 earnings put bioprocessing specialist ba - AD HOC NEWS
BNY Mellon Mid Cap Multi-Strategy Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen Corp. 2026 Annual Meeting Results: Voting Outcomes & Key Shareholder Decisions - Minichart
Repligen shareholders approve board nominees and executive pay at annual meeting - Investing.com
Repligen (NASDAQ: RGEN) holders back board, auditor and pay plan - Stock Titan
5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call - Yahoo Finance
Repligen Corporation (RGEN) Q1 2026 Earnings Beat: Revenue $N/A, EPS $0.48Special Dividend Alert - The Legal Advocate
Repligen (RGEN) Receives Positive Coverage from RBC Capital - GuruFocus
Repligen stock coverage resumed at RBC with outperform rating By Investing.com - Investing.com Nigeria
Repligen stock coverage resumed at RBC with outperform rating - Investing.com
Repligen Corp stock (US7607591002): bioprocessing specialist after earnings and 52?week low - AD HOC NEWS
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repligen Corp Stock (RGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer |
Apr 21 '26 |
Sale |
140.00 |
3,832 |
536,480 |
54,246 |
1.68%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):